 |
[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Re: st: Re: compound outcome variables (not specifically Stata-related)
|
From |
Steven Samuels <[email protected]> |
|
To |
[email protected] |
|
Subject |
Re: st: Re: compound outcome variables (not specifically Stata-related) |
|
Date |
Sat, 24 Jan 2009 13:59:31 -0500 |
A google search on "louise ryan latent" will pick up articles about a
latent variable model for multiple outcomes.
-Steve
On Jan 24, 2009, at 12:44 PM, Diego Navarro wrote:
I recently finished a project for a private consulting shop where I
used principal component analysis to compress a number of
socioeconomic outcome measurements (GDP per capita, unemployment,
diverse measures of education, Gini and Theil indexes, etc.) into a
single State Development Index that was computed for states in
Brazil. (It's like states in the USA). We're actually getting it
published into the mainstream press!
Anyway, that's a datapoint for people treating multiple outcome
issues with Stata.
--
Diego Navarro
(21) 2559-5620
"Writing is not really about meaning, but about land-surveying and
cartography, particularly of lands yet to come" (Mille Plateaux #1.11)
“The first step is to measure what can be easily measured. This is
okay as far as it goes. The second step is to disregard that which
cannot be measured, or give it an arbitrary quantitative value.
This is artificial and misleading. The third step is to presume
that what cannot be measured really is not very important. This is
blindness. The fourth step is to say that what cannot be measured
does not really exist. This is suicide.” (Daniel Yankelovich, 1973)
On 24/01/2009, at 02:03, Joseph Coveney wrote:
A few years ago, Prof. Gary G. Koch (University of North Carolina
at Chapel
Hill) gave a talk here in Tokyo on his researches into the
statistical
handling of "multiple endpoints" (the term he used for what you
describe) in
clinical trials. One of his articles might be a good entry point
into the
literature on the matter. He gave his talk under the auspices of
the Drug
Information Association, an organization that is largely focused
on industrial
product-development activities (viz., pharmaceuticals and
biologics), but the
approaches he described can be applied more generally, e.g.,
evaluating
benefits of medical or surgical treatments, or life-style
changes. Tony
Lachenbruch already mentioned the positions that the U.S. Food and
Drug
Administration takes for so-called co-primary outcomes and multiple
primary outcomes in the context of granting or denying sales
authorizations
for medical products. Professor Koch's talk covered those, but
also broached
the topic of using the endpoints in a compound, or joint, manner
(as if
combining them into a single index of treatment response), and
addressed some
of the various approaches of doing that and their associated
problems. The
U.S. Food and Drug Administration allows these latter approaches
in selected
cases, for example, I believe that there is such a compounded
index for
rheumatoid arthritis that is widely and frequently used.
Joseph Coveney
Christopher W. Ryan wrote:
I would like to try to do a journal club session for my family
practice
residents on the uses, and especailly the pitfalls, of compound
outcome
variables, like "stroke or myocardial infarction or coronary bypass
surgery." They appear frequently in clinical trial literature. Can
anyone recommend any good articles discussing the issues? Thanks.
*
* For searches and help try:
* http://www.stata.com/help.cgi?search
* http://www.stata.com/support/statalist/faq
* http://www.ats.ucla.edu/stat/stata/
*
* For searches and help try:
* http://www.stata.com/help.cgi?search
* http://www.stata.com/support/statalist/faq
* http://www.ats.ucla.edu/stat/stata/
*
* For searches and help try:
* http://www.stata.com/help.cgi?search
* http://www.stata.com/support/statalist/faq
* http://www.ats.ucla.edu/stat/stata/